All In Biotech

Drug Trial Radar · NCT03059823

A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

325

Actual

Start

Nov 15, 2016

Primary completion

May 22, 2024

Study completion May 22, 2024

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Feb 23, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary goal of this Phase 1 study is to characterize the safety and tolerability of INCMGA00012 and establish the maximum tolerated dose (MTD) of INCMGA00012 administered on either every two week or every four week schedules of administration among patients with solid tumors. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of INCMGA00012 will also be assessed. The purpose of Amendment 5 is to obtain additional safety experience at the newly defined recommended Phase 2 dose of 500 mg every 4 weeks in patients with endometrial cancer, specifically either microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). Additionally, every 3 week (Q3W) flat-dosing will be studied in an additional tumor agnostic cohort.

Conditions

  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors

Interventions

  • retifanlimabDrug

    Anti-PD-1 monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03Time frame: 24 months
  2. MTDTime frame: 24 months

Locations

80 sites in 16 countries. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona

  • South Texas Accelerated Research Therapeutics

    Grand Rapids, Michigan

  • Rutgers Cancer Institute of Nj

    New Brunswick, New Jersey

  • Carolina Bio-Oncology Institute, Pllc

    Huntersville, North Carolina

  • Houston Methodist Hospital

    Houston, Texas

  • University of Texas Md Anderson Cancer Center

    Houston, Texas

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas

  • Virginia Commonwealth University Massey Cancer Center

    Richmond, Virginia

  • Chris Obrien Lifehouse

    Camperdown, New South Wales, Australia

  • St Vincent'S Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Universitair Ziekenhuis (Uz) Leuven

    Leuven, Belgium

  • Centre Hospitalier Universitaire de Liege - Sart Tilman

    Liège, Belgium

  • COMPLEX ONCOLOGY CENTER � BURGAS EOOD

    Burgas, Bulgaria

  • Mc Women'S Health-Nadezhda Eood

    Sofia, Bulgaria

  • Acibadem Cityclinica Mhat Tokuda

    Sofia, Bulgaria

  • Umhat in Oncology

    Sofia, Bulgaria

  • Peking Union Medical College Hospital

    Beijing, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China

  • Beijing Cancer Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Xiangya Hospital Central South University

    Changsha, China

  • Hunan Cancer Hospital

    Changsha, China

  • Sun Yat-Sen Memorial Hospital Sun Yat-Sen University

    Guangzhou, China

  • The First Affiliated Hospital Sun Yat-Sen University

    Guangzhou, China

  • Qilu Hospital of Shandong University

    Jinan, China

  • Yunnan Cancer Hospital

    Kunming, China

  • Zhongda Hospital Southeast University

    Nanjing, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, China

  • The Second Hospital of Shanxi Medical University

    Taiyuan, China

  • Tongji Hospital Huazhong University of Science and Technology

    Wuhan, China

  • The First Affiliated Hospital of Xian Jiaotong University

    Xi'an, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

  • Henan Cancer Hostipal

    Zhengzhou, China

  • Docrates Cancer Center

    Helsinki, Finland

  • Turku University Hospital

    Turku, Finland

  • Institut Bergonie

    Bordeaux, France

  • Centre Leon Berard

    Lyon, France

  • Centre Antoine Lacassagne

    Nice, France

  • Hospital Universitaires de Geneve

    Paris, France

  • Groupe Hospitalier Diaconesses Croix Saint-Simon

    Paris, France

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.